Brivaracetam Amarox: Uses, Dosage & Side Effects
A selective SV2A ligand antiepileptic drug used as adjunctive therapy for partial-onset seizures in patients aged 2 years and older
Brivaracetam Amarox is a prescription antiepileptic medication containing brivaracetam, a highly selective ligand for synaptic vesicle protein 2A (SV2A). It is used as adjunctive therapy (add-on treatment) for partial-onset seizures (focal seizures) with or without secondary generalization in patients aged 2 years and older. Brivaracetam is structurally related to levetiracetam but demonstrates approximately 15–30 times higher affinity for SV2A, enabling effective seizure control at lower doses. Available as 10 mg film-coated tablets, Brivaracetam Amarox is typically administered twice daily and has been shown in pivotal clinical trials to significantly reduce seizure frequency when added to existing antiepileptic regimens.
Quick Facts: Brivaracetam Amarox
Key Takeaways
- Brivaracetam Amarox is an antiepileptic drug that works by selectively binding to synaptic vesicle protein 2A (SV2A), reducing excessive neuronal excitability that causes partial-onset seizures in patients aged 2 years and older.
- It has approximately 15–30 times higher affinity for SV2A compared to levetiracetam, enabling effective seizure control at lower doses with potentially fewer behavioral side effects such as irritability and aggression.
- The recommended starting dose for adults is 50 mg twice daily (total 100 mg/day), which can be adjusted to between 25 mg and 100 mg twice daily (50–200 mg/day) based on individual response and tolerability.
- The most common side effects are drowsiness (somnolence), dizziness, and fatigue, which are generally mild to moderate and tend to diminish during the first weeks of treatment.
- Brivaracetam should never be stopped abruptly, as sudden discontinuation can lead to increased seizure frequency or status epilepticus; the dose should be gradually tapered over at least one week under medical supervision.
What Is Brivaracetam Amarox and What Is It Used For?
Brivaracetam Amarox contains the active substance brivaracetam, a next-generation antiepileptic drug (AED) that belongs to the chemical class of racetam derivatives. It was developed as a structural analog of levetiracetam with the specific goal of achieving higher affinity and selectivity for its molecular target, synaptic vesicle protein 2A (SV2A). SV2A is a transmembrane glycoprotein found on the surface of synaptic vesicles throughout the central nervous system. These synaptic vesicles store neurotransmitters and release them into the synaptic cleft when neurons fire. By binding to SV2A with high affinity, brivaracetam modulates the process of neurotransmitter release, dampening the excessive and synchronized neuronal firing that characterizes epileptic seizures.
The precise mechanism by which SV2A ligands exert their antiepileptic effect is still an area of active research. However, it is well established that SV2A plays a critical role in regulating the readily releasable pool of synaptic vesicles and fine-tuning neurotransmitter release. Brivaracetam binds to SV2A with approximately 15 to 30 times higher affinity than levetiracetam, as demonstrated in both in vitro binding studies and in vivo pharmacological models. This enhanced affinity translates to more potent anticonvulsant activity at lower plasma concentrations, which is a key pharmacological advantage. In preclinical models of epilepsy, brivaracetam has demonstrated broad-spectrum anticonvulsant properties, including efficacy against partial seizures, generalized seizures, and status epilepticus.
Brivaracetam also has a notably more favorable lipophilicity profile compared to levetiracetam. This means it crosses the blood-brain barrier more rapidly, achieving therapeutic concentrations in the brain within minutes of oral administration. In electroencephalographic (EEG) studies, significant suppression of epileptiform activity has been observed as early as 30 minutes after a single oral dose. This rapid onset of central nervous system activity is clinically relevant, particularly in situations where swift seizure control is needed.
Brivaracetam Amarox is indicated as adjunctive therapy for the treatment of partial-onset seizures (also known as focal seizures) with or without secondary generalization in patients aged 2 years and older. The term "adjunctive therapy" means that brivaracetam is added to one or more existing antiepileptic medications that a patient is already taking. Partial-onset seizures originate from a localized area of one cerebral hemisphere and may remain confined to that area (simple or complex partial seizures) or spread to involve both hemispheres (secondary generalization, also known as focal to bilateral tonic-clonic seizures). Partial-onset seizures are the most common seizure type in adult epilepsy, accounting for approximately 60% of all seizures.
The clinical efficacy of brivaracetam was established in three pivotal phase III randomized, double-blind, placebo-controlled trials (N01253, N01254, and N01358) involving a total of over 1,550 adult patients with uncontrolled partial-onset seizures despite treatment with one to three concomitant antiepileptic drugs. In these trials, patients receiving brivaracetam at doses of 50 mg/day, 100 mg/day, and 200 mg/day showed statistically significant reductions in seizure frequency compared with placebo over the 12-week treatment period. The 50% responder rate (the proportion of patients achieving at least a 50% reduction in seizure frequency) was significantly higher in the brivaracetam groups compared with placebo, with approximately 32–38% of patients on brivaracetam 100 mg/day achieving this benchmark compared with 16–22% on placebo.
Brivaracetam was first approved by the European Medicines Agency (EMA) in January 2016 and by the U.S. Food and Drug Administration (FDA) in February 2016 under the brand name Briviact. Since then, it has been approved in over 60 countries worldwide. Brivaracetam Amarox is a generic formulation containing the same active substance and is bioequivalent to the originator product. The International League Against Epilepsy (ILAE) and the National Institute for Health and Care Excellence (NICE) have recognized brivaracetam as a valuable treatment option for focal epilepsy, particularly in patients who have not achieved adequate seizure control with other antiepileptic drugs.
The SV2A protein has emerged as one of the most important molecular targets in epilepsy pharmacology. Research has shown that SV2A expression is reduced in the hippocampus of patients with temporal lobe epilepsy, and that the degree of SV2A reduction correlates with increased seizure severity. By selectively binding to and modulating SV2A function, brivaracetam addresses a key pathophysiological mechanism in focal epilepsy while minimizing off-target effects on other neurotransmitter systems.
What Should You Know Before Taking Brivaracetam Amarox?
Contraindications
The primary contraindication to Brivaracetam Amarox is hypersensitivity (allergy) to the active substance brivaracetam, to other pyrrolidone derivatives (such as levetiracetam or piracetam), or to any of the excipients listed in the composition. If you have previously experienced an allergic reaction to any of these substances, you must not take Brivaracetam Amarox. Allergic reactions can range from mild skin rashes to severe anaphylaxis, which is a medical emergency requiring immediate treatment.
While there are no other absolute contraindications listed in the summary of product characteristics, several clinical situations require careful consideration and discussion with your prescribing physician before starting treatment. Brivaracetam should be used with particular caution in patients with severe hepatic impairment, as the drug is primarily metabolized by the liver and exposure is significantly increased in these patients.
Warnings and Precautions
Antiepileptic drugs, including brivaracetam, have been associated with an increased risk of suicidal thoughts and behavior. Patients, caregivers, and family members should be alert for the emergence or worsening of depression, suicidal thoughts or behavior, unusual changes in mood, or any other concerning behavioral changes. If such symptoms occur, contact your healthcare provider immediately. Do not stop taking brivaracetam without medical advice, as abrupt discontinuation can worsen seizures.
Before starting Brivaracetam Amarox, discuss the following with your healthcare provider:
- Depression and psychiatric disorders: Brivaracetam, like other antiepileptic drugs, has been associated with psychiatric adverse effects including depression, anxiety, irritability, aggression, and in rare cases, psychotic symptoms. Patients with a pre-existing history of psychiatric disorders should be monitored closely. In clinical trials, psychiatric adverse events were reported in approximately 13% of brivaracetam-treated patients compared with 8% of placebo-treated patients. However, the rates of behavioral side effects such as irritability and aggression appear to be lower with brivaracetam than with levetiracetam, which may be relevant for patients switching between these two medications.
- Suicidal ideation and behavior: A meta-analysis by the FDA of antiepileptic drugs identified a small but statistically significant increased risk of suicidal ideation and behavior across the drug class. This risk was observed as early as one week after starting treatment and persisted throughout the study period. Patients should be monitored for signs of depression, suicidal thoughts, or unusual changes in behavior, particularly during the first few months of treatment or after dose adjustments.
- Hepatic impairment: Brivaracetam is primarily metabolized by the liver through hydrolysis (via amidase) and hydroxylation (via CYP2C19). In patients with moderate hepatic impairment (Child-Pugh B), plasma concentrations of brivaracetam are increased by approximately 50%. In patients with severe hepatic impairment (Child-Pugh C), exposure is increased by approximately 59%. Dose adjustments may be necessary, and patients with liver disease should be monitored regularly.
- Dizziness and somnolence: Drowsiness and dizziness are among the most common side effects of brivaracetam and can impair the ability to drive or operate machinery. Patients should be advised not to drive or engage in potentially hazardous activities until they have gained sufficient experience with the medication to assess whether it adversely affects their ability to perform such tasks.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, it is critically important to discuss this with your doctor before starting or continuing Brivaracetam Amarox. All antiepileptic drugs carry some degree of risk during pregnancy, including potential teratogenic effects (the risk of causing birth defects). However, uncontrolled seizures during pregnancy also pose serious risks to both the mother and the developing baby, including physical injury, fetal hypoxia, and in severe cases, maternal or fetal death.
Animal reproductive toxicity studies with brivaracetam have shown developmental effects (increased skeletal variations, reduced fetal weights, and embryotoxicity) at doses associated with maternal toxicity. There are limited data from the use of brivaracetam in pregnant women. Based on the available evidence, brivaracetam should not be used during pregnancy unless the potential benefit clearly outweighs the potential risk, as determined by your neurologist or epileptologist in careful discussion with you. Women of childbearing potential should use effective contraception during treatment.
Brivaracetam has been shown to be excreted in the milk of lactating rats, but it is not known whether it is excreted in human breast milk. A risk to the newborn or infant cannot be excluded. The decision whether to discontinue breastfeeding or to discontinue brivaracetam therapy should be made in consultation with your doctor, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. If you become pregnant while taking Brivaracetam Amarox, you should be enrolled in a pregnancy registry to monitor outcomes.
If you discover that you are pregnant, do NOT stop taking Brivaracetam Amarox without first consulting your doctor. Abrupt discontinuation of any antiepileptic drug can lead to breakthrough seizures or status epilepticus, which pose a serious risk to both you and your baby. Your doctor will help you weigh the risks and benefits and may adjust your treatment plan accordingly.
Driving and Operating Machinery
Brivaracetam Amarox may cause somnolence (drowsiness) and dizziness, which can impair the ability to drive vehicles and operate machinery. Patients should be advised not to drive, operate complex machinery, or engage in other potentially hazardous activities until they have sufficient experience with brivaracetam to determine whether it adversely affects their cognitive and motor function. In many jurisdictions, individuals with epilepsy are subject to specific driving regulations, and you should consult your local driving authority and your doctor regarding your fitness to drive.
Children and Adolescents
Brivaracetam Amarox is approved for use in children aged 2 years and older for the adjunctive treatment of partial-onset seizures. In pediatric patients, the dose is calculated based on body weight. The safety and efficacy in children below 2 years of age have not been established. If your child has been prescribed Brivaracetam Amarox, ensure that the dose is administered accurately using an appropriate measuring device, and follow your doctor's instructions regarding dose titration.
How Does Brivaracetam Amarox Interact with Other Drugs?
One of the advantages of brivaracetam compared to several other antiepileptic drugs is its relatively favorable drug interaction profile. Brivaracetam is primarily metabolized through hydrolysis by amidase enzymes and through CYP2C19-mediated hydroxylation. It does not undergo significant metabolism through CYP3A4, which is the cytochrome P450 isoenzyme responsible for the metabolism of the widest range of medications. This pharmacokinetic profile contributes to a relatively limited potential for drug-drug interactions.
However, some clinically relevant interactions have been identified, and patients and healthcare providers should be aware of these when combining brivaracetam with other medications. The most important interactions are summarized in the table below.
| Interacting Drug | Effect | Clinical Significance | Action Required |
|---|---|---|---|
| Carbamazepine | Increases carbamazepine-epoxide (active metabolite) by ~20%; carbamazepine reduces brivaracetam levels by ~26% | Moderate | Monitor for carbamazepine toxicity (dizziness, diplopia, ataxia); dose adjustment of carbamazepine may be needed |
| Phenytoin | Increases phenytoin plasma levels by ~20%; phenytoin reduces brivaracetam levels by ~21% | Moderate | Monitor phenytoin levels; dose adjustment of phenytoin may be necessary |
| Phenobarbital / Primidone | Strong enzyme inducers that may reduce brivaracetam levels | Low to moderate | Monitor seizure control; brivaracetam dose increase may be needed |
| Rifampicin | Reduces brivaracetam plasma levels by ~45% | High | Consider brivaracetam dose increase during rifampicin co-administration; monitor seizure frequency |
| St John’s Wort | May reduce brivaracetam levels through enzyme induction | Moderate | Avoid concomitant use; if used, monitor seizure control |
| Levetiracetam | No pharmacokinetic interaction, but both drugs compete for SV2A binding | Low (pharmacodynamic) | Co-administration offers no additional benefit over optimal dosing of either drug alone; generally not recommended |
| Hormonal contraceptives | No clinically significant effect on ethinylestradiol or levonorgestrel | None | No dose adjustment needed; contraceptive efficacy maintained |
Brivaracetam is a reversible inhibitor of CYP2C19 in vitro. At therapeutic doses, it does not significantly affect the pharmacokinetics of omeprazole (a CYP2C19 substrate), suggesting that in vivo inhibition of CYP2C19 is minimal at clinically relevant concentrations. However, caution is advised with drugs that have a narrow therapeutic index and are primarily metabolized by CYP2C19.
It is important to inform your doctor or pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. This is particularly important for patients with epilepsy, who often take multiple medications simultaneously. Your doctor will assess the potential for interactions and make appropriate dose adjustments if necessary.
Alcohol
Patients should avoid or minimize alcohol consumption while taking Brivaracetam Amarox. Both brivaracetam and alcohol act as central nervous system (CNS) depressants, and their combined use can enhance sedative effects such as drowsiness, dizziness, and impaired cognitive function. A pharmacokinetic interaction study showed that brivaracetam does not alter the pharmacokinetics of ethanol, and ethanol does not alter brivaracetam pharmacokinetics. However, the pharmacodynamic (additive sedative) interaction remains clinically relevant.
Unlike many older antiepileptic medications such as carbamazepine, phenytoin, and valproate, brivaracetam does not significantly induce or inhibit the major hepatic CYP450 enzymes at therapeutic doses. This means it is less likely to alter the blood levels of other medications, making it easier to manage in patients who require polytherapy. Notably, brivaracetam does not reduce the effectiveness of hormonal contraceptives, which is an important consideration for women of childbearing age.
What Is the Correct Dosage of Brivaracetam Amarox?
Brivaracetam Amarox should always be taken exactly as prescribed by your doctor. Do not change your dose or stop taking this medication without consulting your healthcare provider. The tablets should be swallowed whole with a glass of water and may be taken with or without food. Taking the medication at approximately the same times each day helps maintain steady blood levels and optimizes seizure control.
Adults and Adolescents (50 kg and Above)
| Phase | Dose | Frequency | Total Daily Dose |
|---|---|---|---|
| Starting dose | 50 mg | Twice daily | 100 mg/day |
| Minimum dose | 25 mg | Twice daily | 50 mg/day |
| Maximum dose | 100 mg | Twice daily | 200 mg/day |
Treatment is typically initiated at 50 mg twice daily. Based on individual patient response and tolerability, the dose may be adjusted within the range of 25 mg to 100 mg twice daily. Dose adjustments should be made in consultation with your prescribing physician and are usually implemented over a period of one to two weeks. Clinical studies have shown that the 100 mg/day and 200 mg/day doses provide statistically significant seizure reduction compared with placebo, while the 50 mg/day dose also demonstrated efficacy in some trials. The Brivaracetam Amarox 10 mg tablet strength is particularly useful for achieving the 25 mg dose (2.5 tablets) or for gradual titration in patients who are sensitive to medication changes.
Children (2 to 17 Years, Under 50 kg)
In pediatric patients weighing less than 50 kg, the dose of brivaracetam is based on body weight. The recommended starting dose is 1 mg/kg twice daily, with a therapeutic range of 0.5 mg/kg to 2 mg/kg twice daily. For children who require precise dosing, an oral solution formulation may be more appropriate than tablets. However, the 10 mg tablet can be useful for older children whose weight-based dosing aligns with available tablet strengths.
| Body Weight | Starting Dose | Dose Range | Maximum Daily Dose |
|---|---|---|---|
| 10–20 kg | 0.5–1 mg/kg twice daily | 0.5–2 mg/kg twice daily | 4 mg/kg/day (max 200 mg/day) |
| 20–50 kg | 0.5–1 mg/kg twice daily | 0.5–2 mg/kg twice daily | 4 mg/kg/day (max 200 mg/day) |
| ≥50 kg | 50 mg twice daily | 25–100 mg twice daily | 200 mg/day |
Elderly Patients
No specific dose adjustment is required for elderly patients (aged 65 years and older) with normal renal and hepatic function. However, there is limited clinical experience with brivaracetam in patients over 65 years of age, as elderly patients were underrepresented in clinical trials. Given that elderly patients are more likely to have reduced hepatic and renal function, concurrent illnesses, and polypharmacy, careful dose titration and clinical monitoring are recommended. Starting at the lower end of the dosing range and titrating slowly may be prudent in this population.
Hepatic Impairment
For patients with hepatic impairment of any severity (Child-Pugh A, B, or C), the recommended starting dose is 25 mg twice daily, with a maximum recommended dose of 75 mg twice daily (150 mg/day). Brivaracetam is extensively metabolized by the liver, and plasma concentrations are increased by approximately 50% in moderate hepatic impairment and approximately 59% in severe hepatic impairment. Close monitoring is essential in these patients.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for a forgotten dose. Maintaining a consistent dosing schedule is important for optimal seizure control, so consider setting a daily alarm or using a pill organizer to help you remember your medication.
Overdose
If you have taken more Brivaracetam Amarox than prescribed, contact your doctor or seek emergency medical attention immediately. There is limited clinical experience with brivaracetam overdose. In clinical trials, adverse events reported after an overdose of brivaracetam included dizziness, nausea, somnolence, and vomiting. There is no specific antidote for brivaracetam overdose. Treatment should be supportive, including monitoring of vital signs and observation of the patient's clinical status. Hemodialysis is not expected to be effective in removing brivaracetam, as only about 8.6% of the dose is excreted unchanged by the kidneys.
If your doctor decides to stop your treatment with Brivaracetam Amarox, the dose must be gradually reduced over a period of at least one week. Abrupt discontinuation of any antiepileptic drug, including brivaracetam, can lead to increased seizure frequency, prolonged seizures, or status epilepticus (a continuous seizure lasting more than 5 minutes), which is a medical emergency. Always follow your doctor's tapering schedule.
What Are the Side Effects of Brivaracetam Amarox?
Like all medicines, Brivaracetam Amarox can cause side effects, although not everyone who takes it will experience them. The side effects observed during clinical trials and post-marketing surveillance are categorized below by their frequency of occurrence. Most side effects were mild to moderate in severity and occurred more frequently during the initial weeks of treatment before gradually diminishing as the body adjusted to the medication.
In the three pivotal phase III clinical trials, the overall adverse event rate was higher in brivaracetam-treated patients (approximately 61–68%) compared with placebo (approximately 52–56%). However, the discontinuation rate due to adverse events was relatively low (approximately 6–8% for brivaracetam versus 3–5% for placebo), indicating that most side effects were tolerable. The safety profile has been consistent across short-term studies and long-term extension trials lasting up to 8 years of treatment.
Very Common
May affect more than 1 in 10 people
- Somnolence (drowsiness, sleepiness)
- Dizziness
Common
May affect up to 1 in 10 people
- Fatigue (tiredness)
- Nausea
- Vomiting
- Depression
- Anxiety
- Insomnia (difficulty sleeping)
- Irritability
- Upper respiratory tract infections (common cold)
- Decreased appetite
- Constipation
- Vertigo (sensation of spinning)
Uncommon
May affect up to 1 in 100 people
- Suicidal ideation (thoughts of self-harm or suicide)
- Aggression
- Agitation
- Psychotic disorder
- Neutropenia (low white blood cell count)
- Abnormal behavior
Rare
May affect up to 1 in 1,000 people
- Suicide attempt
- Hypersensitivity reactions (allergic reactions including angioedema and bronchospasm)
Somnolence (drowsiness) and dizziness were the most frequently reported side effects in clinical trials. Somnolence was reported in approximately 14–18% of brivaracetam-treated patients (versus 7–8% with placebo), and dizziness was reported in approximately 10–12% (versus 5–6% with placebo). These effects were generally most pronounced during the first weeks of treatment and diminished over time. Most cases were mild to moderate in severity. Patients should be aware that drowsiness and dizziness may impair their ability to drive and operate machinery, and should take appropriate precautions until they know how the medication affects them.
Psychiatric adverse effects deserve particular attention. While brivaracetam has been associated with depression, anxiety, irritability, and agitation, clinical data suggest that the rates of behavioral side effects — particularly irritability and aggression — may be lower with brivaracetam compared to levetiracetam. In a study of patients who were switched from levetiracetam to brivaracetam specifically because of behavioral side effects on levetiracetam, a majority of patients experienced an improvement in their behavioral symptoms after the switch. This finding is clinically significant, as behavioral side effects are among the most common reasons for discontinuation of levetiracetam.
Suicidal ideation and behavior, while uncommon, represent a serious concern with all antiepileptic drugs. Patients and their families should be alert for any emergence or worsening of depression, suicidal thoughts, unusual changes in mood or behavior, and should report any such symptoms to their healthcare provider immediately. It is important to note that epilepsy itself is associated with an increased risk of depression and suicidality, independent of antiepileptic drug treatment.
Long-term safety data from extension studies spanning up to 8 years of treatment have shown that the safety profile of brivaracetam remains consistent over time, with no new safety signals emerging during prolonged use. Weight changes have not been identified as a significant side effect, which is an advantage over some other antiepileptic drugs (such as valproate, which is associated with weight gain, or topiramate, which is associated with weight loss).
Contact your doctor or emergency services immediately if you experience: thoughts of harming yourself or suicide; severe allergic reaction (difficulty breathing, swelling of face, lips, tongue, or throat); severe skin reactions; significant behavioral changes such as extreme agitation, aggression, or psychotic symptoms; or a significant increase in seizure frequency. If someone experiences a seizure lasting more than 5 minutes, call emergency services immediately.
How Should You Store Brivaracetam Amarox?
Proper storage of medication is essential to maintain its quality, safety, and effectiveness throughout the shelf life. Film-coated tablets like Brivaracetam Amarox are formulated to be stable under standard storage conditions, but exposure to excessive heat, moisture, or light can degrade the active ingredient and compromise the tablet's coating, potentially affecting its efficacy and safety.
Follow these storage guidelines carefully:
- Temperature: Store at room temperature, below 30°C (86°F). Do not expose to excessive heat, direct sunlight, or freezing temperatures. Avoid storing in the bathroom, where humidity and temperature fluctuations are common.
- Packaging: Keep the tablets in the original blister package or container to protect from moisture and light. Do not transfer tablets to a pill organizer for more than one week at a time, as prolonged exposure to ambient moisture can affect the film coating.
- Keep out of reach of children: Store in a secure location that is not accessible to children. Accidental ingestion of antiepileptic medications by children can be dangerous and requires immediate medical attention.
- Expiration date: Do not use Brivaracetam Amarox after the expiration date (EXP) printed on the blister or packaging. The expiration date refers to the last day of that month. If you notice that your medication has expired, return it to your pharmacy for proper disposal.
- Inspection: Before taking each dose, briefly inspect the tablet. It should be intact, with no visible signs of damage, discoloration, or crumbling. If the tablets appear different from usual, do not use them and consult your pharmacist.
- Disposal: Do not throw unused or expired medications into household waste or flush them down the toilet. Return them to your pharmacy for safe disposal according to local environmental guidelines. Many pharmacies participate in medication take-back programs.
When traveling with Brivaracetam Amarox, keep the medication in your carry-on luggage rather than checked baggage to avoid temperature extremes in the cargo hold. Carry the medication in its original packaging along with a copy of your prescription or a letter from your doctor, particularly when traveling internationally. Ensure you bring enough medication for the duration of your trip plus a few days' extra supply in case of travel delays.
What Does Brivaracetam Amarox Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical ingredients. Below is a detailed breakdown of the composition of Brivaracetam Amarox 10 mg film-coated tablets.
Active Ingredient
The active substance is brivaracetam, a chemical compound with the systematic name (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide. Each film-coated tablet contains 10 mg of brivaracetam. Brivaracetam is a white to off-white crystalline powder that is freely soluble in water. It is the (2S,4R)-enantiomer, and its stereochemistry is critical for its high-affinity binding to SV2A.
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Brivaracetam | Active substance (antiepileptic) | 10 mg per tablet |
| Croscarmellose sodium | Disintegrant | Aids tablet disintegration in the GI tract |
| Lactose monohydrate | Filler / diluent | Contains lactose — relevant for lactose-intolerant patients |
| Microcrystalline cellulose | Filler / binder | Provides tablet structure |
| Magnesium stearate | Lubricant | Prevents tablet sticking during manufacturing |
| Polyvinyl alcohol | Film coating agent | Part of the tablet film coating |
| Titanium dioxide (E171) | Colorant / opacifier | Provides white appearance to the coating |
| Macrogol (polyethylene glycol) | Plasticizer | Improves coating flexibility |
| Talc | Anti-adherent | Prevents coating from sticking |
The 10 mg film-coated tablets are white to off-white, round, with “b10” debossed on one side. The film coating serves multiple purposes: it protects the active ingredient from degradation by moisture and light, masks any unpleasant taste of the core tablet, and facilitates swallowing.
Brivaracetam Amarox tablets contain lactose monohydrate. Patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. The amount of lactose per tablet is small and is unlikely to cause symptoms in most patients with mild lactose intolerance.
Frequently Asked Questions About Brivaracetam Amarox
Brivaracetam Amarox is used as adjunctive therapy (add-on treatment) for partial-onset seizures (focal seizures) with or without secondary generalization in patients aged 2 years and older with epilepsy. It is not typically used as the sole antiepileptic medication (monotherapy), but rather added to one or more existing antiepileptic drugs to improve seizure control. Partial-onset seizures are the most common seizure type in adults, originating from a specific area of the brain and potentially spreading to involve the entire brain.
Both brivaracetam and levetiracetam work by binding to the same molecular target, synaptic vesicle protein 2A (SV2A). However, brivaracetam has approximately 15–30 times higher affinity for SV2A compared to levetiracetam. This means it can achieve effective seizure control at lower doses. Brivaracetam also penetrates the brain more rapidly due to its higher lipophilicity. Importantly, clinical experience suggests that brivaracetam may have a more favorable behavioral side effect profile, with lower rates of irritability, aggression, and mood disturbances compared to levetiracetam, making it a potential alternative for patients who experience these side effects on levetiracetam.
Brivaracetam Amarox can cause drowsiness and dizziness, which may impair your ability to drive safely. You should not drive or operate heavy machinery until you have sufficient experience with the medication to know whether it affects your alertness and coordination. Additionally, many countries have specific driving regulations for people with epilepsy, often requiring a seizure-free period before driving is permitted. Consult your doctor and your local driving authority for guidance specific to your situation.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and take the next dose at the regular time. Never take a double dose to make up for a missed one. Consistent dosing is important for maintaining steady blood levels and optimal seizure control. Using a pill organizer, mobile phone alarm, or medication reminder app can help you remember to take your medication on time.
Yes, Brivaracetam Amarox is specifically designed to be used as an add-on treatment alongside other antiepileptic drugs. It has a favorable drug interaction profile compared to many older antiepileptics. However, some interactions exist: it can increase levels of phenytoin and the active metabolite of carbamazepine, and strong enzyme inducers like rifampicin can reduce brivaracetam levels. Co-administration with levetiracetam is generally not recommended because both drugs bind to the same target (SV2A) and the combination offers no additional benefit. Always inform your doctor about all medications you take.
No, brivaracetam does not significantly affect the efficacy of hormonal contraceptives, including combined oral contraceptive pills containing ethinylestradiol and levonorgestrel. This is an important advantage over several other antiepileptic drugs (such as carbamazepine, phenytoin, phenobarbital, and topiramate at higher doses) that can reduce the effectiveness of hormonal birth control. No dose adjustment of your contraceptive is needed when taking Brivaracetam Amarox.
References
- European Medicines Agency (EMA). Briviact (brivaracetam) — Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Briviact (brivaracetam) Prescribing Information. Revised 2024. Available at: www.fda.gov
- Klitgaard H, Matagne A, Nicolas JM, et al. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57(4):538–548. doi:10.1111/epi.13340
- Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–1898. doi:10.1111/epi.13220
- Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47–56. doi:10.1111/epi.12432
- Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy & Behavior. 2015;52:165–168. doi:10.1016/j.yebeh.2015.09.005
- World Health Organization (WHO). Epilepsy: A public health imperative. 2019. Available at: www.who.int
- Epilepsy Foundation. Brivaracetam. Available at: www.epilepsy.com
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE Guideline [NG217]. Updated 2024. Available at: www.nice.org.uk
- International League Against Epilepsy (ILAE). Updated ILAE Evidence Review of Antiseizure Medication Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. 2022. Available at: www.ilae.org
Medical Editorial Team
Medical Author
iMedic Clinical Pharmacology Team — Specialists in neuropharmacology and antiepileptic drug therapy with extensive experience in evidence-based pharmaceutical content development.
Medical Reviewer
iMedic Medical Review Board — Independent panel of board-certified neurologists and epileptologists who review all content according to international guidelines (ILAE, EMA, FDA, NICE).
Evidence Standards
Level 1A evidence based on systematic reviews, meta-analyses, and randomized controlled trials. Content follows the GRADE evidence framework and adheres to ILAE treatment guidelines.
Editorial Independence
No pharmaceutical company funding or sponsorship. All content is independently developed and reviewed without commercial influence. See our editorial standards.